Hi-Tech Pharmacal Co. Inc.

Company Description

Hi-Tech makes branded and genetic pharmaceutical products. The company's areas of specialty are in liquid and semi-solid dosages as well as ophthalmic and inhalant products.

Record Results

On Sep 9 Hi-Tech announced record net sales of $43.5 million, up 175% from the same period last year. Net income grew to $8.7 million, up dramatically from $1.5 million one year ago.

Earnings per share came in at 61 cents, more than triple the Zacks Consensus Estimate of 18 cents. This was the company's third surprise in the past 4 quarters.

Analysts React

Following the report the Zacks Consensus Estimate spiked to $1.42, up from 89 cents after the sole covering analyst raised their forecast. This would be the equivalent of an 82% earnings growth rate.

Valuations

Share of HITK are still trading at a good value following the excellent report. They are exchanging hands at about 15 times earnings, with a PEG ratio of 0.7 times.

The Chart

The past 2 quarterly reports have sent shares of HITK flying. Take a look at the chart below, and make sure to keep an eye on that earnings calendar.

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment

Loading Stories...

Related Content

RELATED ARTICLES AGGRESSIVE GROWTH ARCHIVE

Zacks Equity Research: Report For HIT&
N/A	02/02/10
Zacks Blog: HITK Enters Oversold Territory
(HITK)	01/27/10
Zacks Blog: Zacks Releases Four Powerful ''Buy'' Stocks: Hi-Tech Pharmacal Co, T. Rowe Price Group, Inc., Solarfun Power Holdings Co. and Maidenform Brands Inc.
(HITK, TROW, SOLF, MFB)	12/29/09
Aggressive Growth: Hi-Tech Pharmacal Co.
(HITK)	12/29/09
Zacks #1 Rank Top Performers: Top Performer for Thurs: Par Pharmaceutical (PRX)
(HITK)	10/15/09

 Posting Comment...

There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]

Comments (Limit 1000 Characters - Used: 0)

Please provide your comments here... Display Name: Email Address:  

 Loading Comments...

Be the first to comment on this article!